Overview

Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study

Status:
Active, not recruiting

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

A) Phase 1: To determine the maximal tolerated dose (MTD) of lenalidomide that can be safely added to high-dose melphalan prior to autologous stem cell transplantation (ASCT). B) Phase 2: To determine whether the addition of high-dose lenalidomide to ASCT followed by maintenance standard-dose lenalidomide improves the response rate and duration of response for relapsed multiple myeloma (RMM).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Weill Medical College of Cornell University

Collaborators:

Celgene
Celgene Corporation

Treatments:

Lenalidomide
Melphalan
Thalidomide